ResearcherMacroGenics (United States)Active in the last 2 years

Paul A. Moore

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6057-7539; OpenAlex author ID A5023294934. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 12

Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

David Tsai Ting · 1 shared paper, 2024 · strength 0.17
- Paper Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2024.216713 ↗
Yurie Sekigami · 1 shared paper, 2024 · strength 0.17
- Paper Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2024.216713 ↗
Cristina R. Ferrone · 1 shared paper, 2024 · strength 0.17
- Paper Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2024.216713 ↗
Lei Cai · 1 shared paper, 2024 · strength 0.17
- Paper Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2024.216713 ↗
Theodoros P. Michelakos · 1 shared paper, 2024 · strength 0.17
- Paper Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2024.216713 ↗
Marco Ventin · 1 shared paper, 2024 · strength 0.17
- Paper Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2024.216713 ↗
Giulia Cattaneo · 1 shared paper, 2024 · strength 0.17
- Paper Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2024.216713 ↗
Soldano Ferrone · 1 shared paper, 2024 · strength 0.17
- Paper Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2024.216713 ↗
Xinhui Wang · 1 shared paper, 2024 · strength 0.17
- Paper Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2024.216713 ↗
Vikram Deshpande · 1 shared paper, 2024 · strength 0.17
- Paper Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2024.216713 ↗
Nabeel M. Bardeesy · 1 shared paper, 2024 · strength 0.17
- Paper Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. DOI 10.1016/j.canlet.2024.216713 ↗
Candy N. Lee · 1 shared paper, 2012 · strength 0.03
- Paper RNA interference characterization of proteins discovered by proteomic analysis of pancreatic cancer reveals function in… DOI 10.1097/mpa.0b013e3182236385 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.